Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)...  Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, ... announced that its Chairman and CEO, Alan Shortall ... 26th Annual Healthcare Conference at the New York Palace ... 2014. The conference presentation will be ... Webcast. To listen, please go to: http://ir.unilife.com/events.cfm . ...
Breaking Medicine Technology:KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
(Date:11/27/2014)... 27, 2014 In a world ... to sleep has lessened, and due to the ... quality of sleep has eroded. According to Web ... the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This remarkably ... by an incalculable amount, leading not only to ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 "As a ... embarrassing side effects of urinary incontinence," said an inventor ... and developed this specialized accessory to prevent leakage and ... Incontinence to absorb urine leakage. This prevents stains on ... potential embarrassment. The pad ensures that the individual has ...
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
(Date:11/27/2014)... NV (PRWEB) November 27, 2014 Now ... shopping season has officially launched, Emassagechair.com has ... Cyber Monday Discount Event. , Negotiating on behalf ... with top massage chair brands, Emassagechair.com has generated significant ... best deals and biggest discounts yet. , Shoppers are ...
Breaking Medicine News(10 mins):Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... A recent, large-scale study on cat intestinal cancer has provided ... the findings could ultimately benefit humans. "We are looking ... find common risk factors," said Kim Selting, associate teaching professor ... mentored a former resident, Kerry Rissetto, as she examined intestinal ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- The influenza ... circulating in the United States at least four months before ... year, researchers say. Their finding comes from examinations of ... of 68 American soldiers who died of respiratory infections in ...
... trial evaluating whether daily use of an oral tablet ... infection in women is being modified because an interim ... of the study products, oral tenofovir, marketed under the ... safety monitoring board (DSMB) recommended that the Vaginal and ...
... Women generally have a lower risk of developing cardiovascular disease ... with lower rates of high blood pressure and a tendency ... of LDL ("bad") cholesterol. Then comes the great equalizer: menopause. ... than men and their cholesterol levels tend to worsen, even ...
... Survey of Children,s Health indicates 31 percent of Missouri ... physical activity requirements for students and nutritional standards for ... new study from the University of Missouri shows Jump ... effective in changing unhealthy youth behaviors. JIA aims ...
... likely than doctors in other areas to encourage parents to ... to a new study. The results are alarming because ... cancer and studies show that Appalachian women are more ... than women living elsewhere. "We found that pediatricians in ...
Cached Medicine News:Health News:University of Missouri study finds risk factors for cat cancer, could have human implications 2Health News:NIH modifies 'VOICE' HIV prevention study in women 2Health News:Physiology of cardiovascular disease: Gender disparities 2Health News:Students 'jump into action' for better health 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 2Health News:Pediatricians in Appalachia less likely to recommend HPV vaccine 3
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: